Abstract | PURPOSE: METHODS: Group A: Ten-week-old, LH(BETA)T(AG) mice received a single subconjunctival injection of anecortave acetate (1200, 600, 300, and 150 microg) delivered to right eyes only. Group B: Ten-week-old, LH(BETA)T(AG) mice received a single subconjunctival injection of anecortave acetate (600, 300, and 150 microg) delivered to right eyes only, either during a cycle of carboplatin (six subconjunctival deliveries) or after the completed cycle. Carboplatin was delivered at the subtherapeutic concentration of 62.5 microg. All animals were euthanatized at 16 weeks of age, and the eyes were examined histopathologically. RESULTS: CONCLUSIONS:
|
Authors | Maria-Elena Jockovich, Timothy G Murray, Erika Escalona-Benz, Eleut Hernandez, William Feuer |
Journal | Investigative ophthalmology & visual science
(Invest Ophthalmol Vis Sci)
Vol. 47
Issue 4
Pg. 1264-8
(Apr 2006)
ISSN: 0146-0404 [Print] United States |
PMID | 16565356
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Pregnadienediols
- Carboplatin
- anecortave acetate
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Carboplatin
(therapeutic use)
- Chemotherapy, Adjuvant
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Injections
- Mice
- Mice, Transgenic
- Pregnadienediols
(therapeutic use)
- Retinal Neoplasms
(drug therapy)
- Retinoblastoma
(drug therapy)
|